Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16885720rdf:typepubmed:Citationlld:pubmed
pubmed-article:16885720lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:16885720lifeskim:mentionsumls-concept:C0032105lld:lifeskim
pubmed-article:16885720lifeskim:mentionsumls-concept:C0064113lld:lifeskim
pubmed-article:16885720lifeskim:mentionsumls-concept:C0680730lld:lifeskim
pubmed-article:16885720lifeskim:mentionsumls-concept:C1511790lld:lifeskim
pubmed-article:16885720lifeskim:mentionsumls-concept:C0205177lld:lifeskim
pubmed-article:16885720lifeskim:mentionsumls-concept:C0870883lld:lifeskim
pubmed-article:16885720lifeskim:mentionsumls-concept:C1148554lld:lifeskim
pubmed-article:16885720lifeskim:mentionsumls-concept:C0008565lld:lifeskim
pubmed-article:16885720lifeskim:mentionsumls-concept:C0332324lld:lifeskim
pubmed-article:16885720pubmed:issue4lld:pubmed
pubmed-article:16885720pubmed:dateCreated2006-8-3lld:pubmed
pubmed-article:16885720pubmed:abstractTextA simple and sensitive column-switching high-performance liquid chromatographic method for the simultaneous determination of itraconazole (ITZ) and its active metabolite, hydroxyitraconazole (HIT) in human plasma is described. ITZ, HIT, and an internal standard, R051012, were extracted from 1 mL of alkalinized plasma sample using n-heptane-chloroform (60:40, vol/vol). The extract was injected onto column I (TSK precolumn BSA-ODS/S, 5 microm, 10 x 4.6 mm ID) for clean-up and column II (Develosil C8-5 column, 5 microm, 150 x 4.6 mm ID) for separation. The mobile phase consisted of phosphate buffer-acetonitrile (68:32 vol/vol, pH 6.0) for clean-up and phosphate buffer-acetonitrile (35:65 vol/vol, pH 6.0) for separation. The peaks were monitored with an ultraviolet detector set at a wavelength of 263 nm, and total time for chromatographic separation was about 24 minutes. The validated concentration ranges of this method were 3 to 500 ng/mL for ITZ and 3 to 1000 ng/mL for HIT. Mean recoveries were 59.7% for ITZ and 72.8% for HIT. Intraday and interday coefficients of variation were less than 4.6% and 5.0% for ITZ, and 4.6% and 4.9% for HIT at the different concentrations. The limit of quantification was 3 ng/mL for both ITZ and HIT. This method was suitable for therapeutic drug monitoring of ITZ and HIT, and was applied to pharmacokinetic studies in human volunteers.lld:pubmed
pubmed-article:16885720pubmed:languageenglld:pubmed
pubmed-article:16885720pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16885720pubmed:citationSubsetIMlld:pubmed
pubmed-article:16885720pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16885720pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16885720pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16885720pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16885720pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16885720pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16885720pubmed:statusMEDLINElld:pubmed
pubmed-article:16885720pubmed:monthAuglld:pubmed
pubmed-article:16885720pubmed:issn0163-4356lld:pubmed
pubmed-article:16885720pubmed:authorpubmed-author:TateishiTomon...lld:pubmed
pubmed-article:16885720pubmed:authorpubmed-author:SugawaraKazun...lld:pubmed
pubmed-article:16885720pubmed:authorpubmed-author:ShimizuMikiko...lld:pubmed
pubmed-article:16885720pubmed:authorpubmed-author:UnoTsukasaTlld:pubmed
pubmed-article:16885720pubmed:issnTypePrintlld:pubmed
pubmed-article:16885720pubmed:volume28lld:pubmed
pubmed-article:16885720pubmed:ownerNLMlld:pubmed
pubmed-article:16885720pubmed:authorsCompleteYlld:pubmed
pubmed-article:16885720pubmed:pagination526-31lld:pubmed
pubmed-article:16885720pubmed:meshHeadingpubmed-meshheading:16885720...lld:pubmed
pubmed-article:16885720pubmed:meshHeadingpubmed-meshheading:16885720...lld:pubmed
pubmed-article:16885720pubmed:meshHeadingpubmed-meshheading:16885720...lld:pubmed
pubmed-article:16885720pubmed:meshHeadingpubmed-meshheading:16885720...lld:pubmed
pubmed-article:16885720pubmed:meshHeadingpubmed-meshheading:16885720...lld:pubmed
pubmed-article:16885720pubmed:meshHeadingpubmed-meshheading:16885720...lld:pubmed
pubmed-article:16885720pubmed:meshHeadingpubmed-meshheading:16885720...lld:pubmed
pubmed-article:16885720pubmed:meshHeadingpubmed-meshheading:16885720...lld:pubmed
pubmed-article:16885720pubmed:meshHeadingpubmed-meshheading:16885720...lld:pubmed
pubmed-article:16885720pubmed:meshHeadingpubmed-meshheading:16885720...lld:pubmed
pubmed-article:16885720pubmed:meshHeadingpubmed-meshheading:16885720...lld:pubmed
pubmed-article:16885720pubmed:meshHeadingpubmed-meshheading:16885720...lld:pubmed
pubmed-article:16885720pubmed:meshHeadingpubmed-meshheading:16885720...lld:pubmed
pubmed-article:16885720pubmed:meshHeadingpubmed-meshheading:16885720...lld:pubmed
pubmed-article:16885720pubmed:meshHeadingpubmed-meshheading:16885720...lld:pubmed
pubmed-article:16885720pubmed:meshHeadingpubmed-meshheading:16885720...lld:pubmed
pubmed-article:16885720pubmed:year2006lld:pubmed
pubmed-article:16885720pubmed:articleTitleSensitive determination of itraconazole and its active metabolite in human plasma by column-switching high-performance liquid chromatography with ultraviolet detection.lld:pubmed
pubmed-article:16885720pubmed:affiliationDepartment of Clinical Pharmacology, Hirosaki University School of Medicine, Hirosaki University Hospital, Hirosaki, Japan. uno-hki@umin.ac.jplld:pubmed
pubmed-article:16885720pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16885720pubmed:publicationTypeClinical Triallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16885720lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16885720lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16885720lld:pubmed